A much awaited trial was one of the late breaking trials presented at the recently concluded #ERAEDTA18 in Copenhagen.

Mike Walsh from McMaster University presented the results of the PEXIVAS trial – which were rapidly Tweeted and caused quite a conversation. Daniel ran a twitter poll with some interesting decisions seen already:


Check out the entire protocol here. It was a 2x2 factorial trial - so not only on plasma exchange, but also low dose steroids in patients with severe ANCA vasculitis. 

Whether you call it positive, negative or successful - it will definitely be a practice changing trial that we will discuss in more depth when it is actually published. Until then, enjoy this twitter moment from Maryam Khosravi: